More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/MI-2 [MALT1 Inhibitor] [1047953-91-2]
Chemical Structure
Chemical Structure
Chemical Structure

MI-2 [MALT1 Inhibitor] [1047953-91-2]

Research Use Only
AG-CR1-3661
AdipoGen Life Sciences
CAS Number1047953-91-2
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight455.7
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    MI-2 [MALT1 Inhibitor] [1047953-91-2]
  • Delivery Days Customer
    10
  • CAS Number
    1047953-91-2
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C19H17Cl3N4O3
  • Molecular Weight
    455.7
  • Scientific Description
    Chemical. CAS: 1047953-91-2. Formula: C19H17Cl3N4O3. MW: 455.7. Synthetic. Highly potent and selective irreversible MALT1 inhibitor (IC50=5.8microM). Binds directly to MALT1 and suppresses protease function. Decreases NF-kappaB activity induced by MALT1. Inhibits cell proliferation and MALT1-mediated cleavage activity. Suppresses human TMD8 and HBL-1 (EC50= ~200nM and ~500nM for HBL-1 and TMD8, respectively) activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines in vitro and xenotransplanted mouse ABC-DLBCL tumors in vivo and primary human ABC-DLBCLs ex vivo. In combination with bryostatin 1 displays selective killing of HIV latently infected CD4+ T cells. Inhibits NF-kappaB and NLRP3 inflammasome activation in macrophages. Decreased production of IL-1beta/IL-18 in PMA-differentiated THP-1 cells and bone marrow derived macrophage via suppressing the activation of NF-kappaB and NLRP3 inflammasome. - Highly potent and selective irreversible MALT1 inhibitor (IC50=5.8microM). Binds directly to MALT1 and suppresses protease function. Decreases NF-kappaB activity induced by MALT1. Inhibits cell proliferation and MALT1-mediated cleavage activity. Suppresses human TMD8 and HBL-1 (EC50= ~200nM and ~500nM for HBL-1 and TMD8, respectively) activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines in vitro and xenotransplanted mouse ABC-DLBCL tumors in vivo and primary human ABC-DLBCLs ex vivo. In combination with bryostatin 1 displays selective killing of HIV latently infected CD4+ T cells. Inhibits NF-kappaB and NLRP3 inflammasome activation in macrophages. Decreased production of IL-1beta/IL-18 in PMA-differentiated THP-1 cells and bone marrow derived macrophage via suppressing the activation of NF-kappaB and NLRP3 inflammasome.
  • SMILES
    COCCOC1=NN(C2=CC=C(NC(CCl)=O)C=C2)C(C3=CC=C(Cl)C(Cl)=C3)=N1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo: L. Fontan, et al.; Cancer Cell 22, 812 (2012)
  • MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-kappaB and NLRP3 inflammasome activation: W. Liu, et al.; Oncotarget 7, 30536 (2016)
  • Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor: H. Li, et al.; AIDS Res. Hum. Retroviruses 32, 174 (2016)